MEDLATEC MenCare Hereditary Cancer Risk Test

MenCare is a hereditary cancer genetic risk assessment offered by MEDLATEC, designed to identify inherited genetic variants associated with increased susceptibility to certain cancers in men.

The test analyses a panel of 10 genes associated with hereditary cancer risk, focusing on prostate, colorectal and stomach cancers.

Unlike blood-based cancer signal screening tests, MenCare evaluates inherited cancer susceptibility. It does not detect whether cancer is currently present.

Cancer Risks Assessed

• Prostate Cancer

Assessment of inherited genetic variants associated with susceptibility to prostate cancer.

• Colorectal Cancer

Analysis of genetic variants that may be associated with hereditary colorectal cancer risk.

• Stomach Cancer

Evaluation of genetic variants associated with inherited susceptibility to certain forms of stomach cancer.

Key Benefits of MenCare

• Personalised Genetic Risk Assessment

MenCare provides information about inherited genetic factors that may influence susceptibility to selected cancers.

• Focused 10-Gene Panel

The test examines 10 genes associated with hereditary cancer risk, focusing on cancers relevant to men's health.

• Supports Preventive Healthcare Planning

Results may help patients and healthcare professionals discuss personalised screening strategies, lifestyle considerations and further genetic evaluation where appropriate.

• Useful for Family Health Discussions

Certain inherited genetic findings may have implications for biological relatives. Genetic counselling can help patients understand whether family members should consider additional assessment.

• Generally a One-Time Genetic Assessment

Because inherited DNA variants are generally stable throughout life, germline genetic testing typically does not require routine annual repetition. Additional testing may be appropriate if genetic knowledge or clinical circumstances change.

Who May Consider MenCare?

MenCare may be considered by individuals who:

• Have a personal or family history of prostate, colorectal or stomach cancer.

• Have relatives diagnosed with cancer at a relatively young age.

• Have multiple relatives affected by related cancer types.

• Want to discuss hereditary cancer risk with a qualified healthcare professional.

• Have been advised to undergo genetic risk assessment.

The decision to undergo testing should be guided by individual medical and family history. A focused 10-gene panel may not cover every hereditary cancer syndrome.

Testing Process

1. Pre-Test Consultation: Review personal medical history, family cancer history and genetic testing suitability.

2. Sample Collection: A biological sample is collected according to MEDLATEC's testing requirements.

3. Genetic Analysis: The laboratory analyses the selected 10-gene panel.

4. Results: Results are generally expected in approximately 15 working days, subject to laboratory confirmation.

5. Genetic Counselling and Follow-Up: A qualified professional may explain the findings and discuss appropriate next steps.

Understanding Your Results

• Pathogenic or Likely Pathogenic Variant

A clinically significant inherited genetic variant may indicate increased susceptibility to certain cancers. It does not mean that cancer is currently present or will definitely develop.

• No Reportable Pathogenic Variant Identified

A negative result does not eliminate hereditary or non-hereditary cancer risk. Other genetic factors, family history and environmental influences may still be relevant.

• Variant of Uncertain Significance (VUS)

Some genetic changes cannot currently be classified as harmful or harmless. Such findings generally should not independently determine medical management.

Key Data

• Test Name: MenCare

• Test Category: Hereditary Cancer Genetic Risk Assessment

• Genetic Panel: 10 Genes

• Cancer Risks Assessed: Prostate, Colorectal and Stomach Cancers

• Purpose: Assessment of Inherited Cancer Susceptibility

• Expected Result Time: Approximately 15 Working Days

Your Healthcare Journey in Vietnam with MediHub

MediHub supports international patients travelling to Vietnam for healthcare services, including genetic testing and preventive healthcare planning.

Our support services may include:

• Healthcare service and genetic testing consultation

• Appointment scheduling with MEDLATEC

• Pre-arrival guidance and preparation

• Visa and travel assistance where required

• Airport transfers and local transportation

• Accommodation arrangements

• Medical interpreter coordination

• Assistance during medical appointments

• Medical results and follow-up coordination

• Travel and tourism arrangements during your stay

Plan Your Genetic Testing Journey in Vietnam

Interested in understanding your hereditary cancer risk?

Contact MediHub for personalised assistance in planning your genetic testing journey in Vietnam. Our team can help coordinate your MenCare appointment, discuss travel arrangements and assist with follow-up planning.

Important Medical Information

MenCare is a hereditary genetic risk assessment, not a test for diagnosing cancer or detecting an existing tumour.

An increased genetic risk does not mean that cancer will necessarily develop, and a negative result does not eliminate cancer risk.

Genetic testing results should be interpreted by appropriately qualified healthcare professionals, ideally with access to genetic counselling. Routine cancer screening and clinical assessment may still be necessary.